Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
July 12 2021 - 4:30PM
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the
appointment of Utpal Koppikar, Chief Financial Officer of Atara
Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve
as the chair of Flexion’s audit committee.
"I am thrilled to welcome Utpal to Flexion’s Board, as his
extensive financial experience leading biotechnology companies
makes him an outstanding addition to our Board of Directors,”
said Michael Clayman, MD, President and Chief Executive
Officer of Flexion Therapeutics. “In addition to Utpal’s
anticipated contributions guiding our corporate strategy, I look
forward to his stewardship and counsel as chair of our audit
committee."
Commenting on his appointment, Mr. Koppikar said, "I am honored
to join Flexion’s Board of Directors at this exciting point in the
company’s evolution. I look forward to supporting Flexion’s
management team and my fellow Directors as we work towards
realizing the full potential of ZILRETTA® and advancing the
company’s two compelling pipeline candidates.”
Mr. Koppikar joined Atara Biotherapeutics in June 2018, and
oversees Finance, Information Technology, and Investor Relations.
Prior to his tenure with Atara, Mr. Koppikar held several senior
financial leadership positions at Gilead Sciences, including Vice
President of Corporate and Operations Finance. During his time
there, he led the three-year financial planning process and
financial integration of Kite Pharma and played a key role as
Gilead’s Vice President of Finance Europe, Middle East and
Australia partnering with commercial for multiple HIV and HCV
product launches. Prior to joining Gilead, he served in multiple
finance roles of increasing responsibility at Amgen.
Mr. Koppikar earned a B.S. in aerospace engineering at the
University of Maryland and received an M.S. in aeronautical and
astronautical engineering from Stanford University. He also holds
an M.B.A. in finance and marketing from The Anderson School at
UCLA.
Indication and Select Important Safety Information for
ZILRETTA (triamcinolone acetonide extended-release
injectable suspension)
Indication: ZILRETTA is indicated as an
intra-articular injection for the management of osteoarthritis pain
of the knee.
Limitation of Use: The efficacy and safety of repeat
administration of ZILRETTA have not been demonstrated.
Contraindication: ZILRETTA is
contraindicated in patients who are hypersensitive to triamcinolone
acetonide, corticosteroids or any components of the product.
Warnings and Precautions:
-
Intra-articular Use Only: ZILRETTA has not
been evaluated and should not be administered by epidural,
intrathecal, intravenous, intraocular, intramuscular, intradermal,
or subcutaneous routes. ZILRETTA should not be considered safe for
epidural or intrathecal administration.
- Serious
Neurologic Adverse Reactions with Epidural and Intrathecal
Administration: Serious neurologic events have been
reported following epidural or intrathecal corticosteroid
administration. Corticosteroids are not approved for this use.
-
Hypersensitivity reactions: Serious reactions
have been reported with triamcinolone acetonide injection.
Institute appropriate care if an anaphylactic reaction occurs.
- Joint
infection and damage: A marked increase in joint
pain, joint swelling, restricted motion, fever and malaise may
suggest septic arthritis. If this occurs, conduct appropriate
evaluation and if confirmed, institute appropriate antimicrobial
treatment.
Adverse Reactions: The most commonly
reported adverse reactions (incidence ≥1%) in clinical studies
included sinusitis, cough, and contusions.
Please
see ZilrettaLabel.com for
full Prescribing Information.
About ZILRETTAOn October 6, 2017, ZILRETTA was
approved by the U.S. FDA as the first and only extended-release
intra-articular therapy for patients confronting
osteoarthritis-related knee pain. ZILRETTA employs proprietary
microsphere technology combining triamcinolone acetonide — a
commonly administered, short-acting corticosteroid — with a poly
lactic-co-glycolic acid (PLGA) matrix to provide extended pain
relief. The pivotal Phase 3 trial on which the approval of ZILRETTA
was based showed that ZILRETTA significantly reduced OA knee pain
for 12 weeks, with some people experiencing pain relief through
Week 16. Learn more at www.zilretta.com.
About Flexion TherapeuticsFlexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of people with musculoskeletal
conditions, beginning with osteoarthritis, the most common form of
arthritis. The Company's core values are focus, ingenuity,
tenacity, transparency and fun. Please
visit flexiontherapeutics.com.
Forward-Looking Statements This press release
contains forward-looking statements that are based on the current
expectations and beliefs of Flexion. Statements in this press
release regarding matters that are not historical facts, including,
but not limited to, statements relating to the future of Flexion;
future contributions of Mr. Koppikar; and potential of ZILRETTA and
future development of Flexion’s pipeline programs, are forward
looking statements. These forward-looking statements are based on
management’s expectations and assumptions as of the date of this
press release and are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include, without limitation; risks related to
commercialization of ZILRETTA and clinical trials, including
potential delays, safety issues, or negative results; the fact that
future results may not be consistent with preliminary results or
results from prior studies or trials; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission (SEC), including under the heading “Risk
Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2020, filed with the SEC on March 10, 2021, and
subsequent filings with the SEC. The forward-looking statements in
this press release speak only as of the date of this press release,
and we undertake no obligation to update or revise any of the
statements. We caution investors not to place considerable reliance
on the forward-looking statements contained in this press
release.
Contact:
Scott YoungVice President, Corporate Communications &
Investor RelationsT: 781-305-7194syoung@flexiontherapeutics.com
Julie DownsAssociate Director, Corporate Communications &
Investor RelationsT: 781-305-7137jdowns@flexiontherapeutics.com
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Sep 2023 to Sep 2024